Table 1.

Baseline data for patients with FSGS treated with adrenocorticotropic hormone

Patient	Age/(yr)/Sex	Race/Ethnicity	FSGS Morphology	Previous Immunosuppression	Steroid Response Category	Time from Diagnosis to Treatment (mo)	Serum Creatinine (mg/dl)	eGFR (ml/min per 1.73 m²)	Proteinuria (mg/g)
Columbia patients
1	42/Male	WNH	NOS	Steroids, MMF, tacrolimus^a	SR	2^b	2.7	28	7000
2	38/Female	BNH	NOS	Steroids, MMF, cyclosporine	SR	56	2.3	31	5046
3	21/Female	WNH	Tip	Steroids, tacrolimus, cyclosporine	SD	12	1.1	67	5200
4	40/Male	WNH	Tip	Steroids, tacrolimus, cyclosporine, MMF	SR	96	1.2	71	2100
5	18/Male	BNH	Tip	Steroids, tacrolimus, MMF	SR	13	2.6	42	11,200
6	46/Male	WNH	NOS	Steroids, cyclophosphamide, MMF, tacrolimus	SD	30	3.2	23	16,800
7	64/Female	WH	Cellular	Steroids, MMF, tacrolimus,	SD	61	1.6	35	10,300
8	60/Female	WNH	Cellular	Steroids, tacrolimus, MMF, cyclosporine	SR	23	2.3	23	2300
9	66/Male	WNH	Tip	Steroids, cyclosporine, MMF	SR	132	1.0	66	1600
10	36/Male	WNH	NOS	Steroids, cyclosporine	SR	96	0.8	116	2200
11	30/Female	WNH	Tip	Steroids, MMF, cyclosporine, tacrolimus	SR	13	3.4	17	8800
12	47/Female	BH	Tip	Steroids, tacrolimus^a	SR	4	3.6	17	15,200

Stanford patients
13	66/Male	WH	NOS	Steroids	SR	14	2.2	30	2020
14	65/Male	WNH	Cellular	None	NA	8	2.7	24	3170
15	64/Male	WNH	NOS	Steroids	SD	22	1.04	76	7240
16	27/Male	WH	NOS	Steroids, cyclosporine	SR	28	2.99	35	2200
17	58/Male	WNH	Tip	None	NA	4	2.2	32	3550
18	29/Male	BNH	Collapsing	Steroids, MMF	SR	6	3.3	28	23,800
19	28/Female	WH	Tip	Cyclosporine	NA	19	0.6	124	4860
20	40/Male	WH	NOS	Steroids	SD	29	1.1	84	2320
21	39/Female	WH	Tip	Steroids, MMF	SR	24	1.7	37	1710
22	69/Female	WNH	Tip	Steroids, tacrolimus	SR	94	0.6	93	4330
23	56/Female	WNH	Cellular	Steroids	SR	2	1.1	56	6560
24	39/Male	WH	Tip	Steroids, cyclosporine	SD	29	1.0	94	2000

eGFR, estimated GFR; WNH, white non-Hispanic; NOS, not otherwise specified; MMF, mycophenolate mofetil; SR, steroid resistant; BNH, black Non-Hispanic; SD, steroid dependent; WH, white Hispanic; BH, black Hispanic; NA, not applicable.
↵a Patients 1 and 12 also underwent plasma exchange therapy.
↵b Patient 1 had undergone four prior renal transplants for recurrent FSGS and was diagnosed with another recurrence 2 months before starting ACTH.